Trial Profile
To Evaluate the Multiple Endocrine Disruption in Patients With Non-small Cell Lung Cancer by the MET/ALK Inhibitor Crizotinib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 13 May 2016 New trial record